COVERSYL ARGININE PLUS
Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
Karakteristik produk
(SPC)
19-04-2024
Beberapa dokumen untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan ke layanan pelanggan kami dan kami akan memberi tahu Anda segera setelah kami bisa mendapatkannya.
Kirim permintaan.
Kirim permintaan.
Bahan aktif:
PERINDOPRIL ARGININE INDAPAMIDE
Tersedia dari:
Imbat Limited
Dosis:
5/1.25 Milligram
Bentuk farmasi:
Film Coated Tablet
Tanggal Otorisasi:
2008-11-14
Karakteristik produk
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Coversyl Arginine Plus 5mg/1.25mg Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 3.395 mg perindopril equivalent to 5mg perindopril arginine and 1.25 mg indapamide.
Excipients : lactose monohydrate
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet.
_Product imported from the UK, Hungary and Poland_
White, rod-shaped film-coated tablet.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of essential hypertension, COVERSYL ARGININE PLUS 5mg/1.25mg film-coated tablet is indicated in patients
whose blood pressure is not adequately controlled on perindopril alone.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oral route
One COVERSYL ARGININE PLUS 5mg/1.25mg film-coated tablet per day as a single dose, preferably to be taken in the
morning, and before a meal.
When possible individual dose titration with the components is recommended. COVERSYL ARGININE PLUS 5mg/1.25mg film-
coated tablet should be used when blood pressure is not adequately controlled on COVERSYL ARGININE PLUS 2.5mg/0.625mg
film-coated tablet (where available).When clinically appropriate, direct change from monotherapy to COVERSYL ARGININE
PLUS 5mg/1.25mg film-coated tablet may be considered.
_Elderly (see section 4.4)_
Treatment should be initiated after considering blood pressure response and renal function.
_Patients with renal impairment (see section 4.4)_
In severe renal impairment (creatinine clearance below 30 ml/min), treatment is contraindicated.
In patients with moderate renal impairment (creatinine clearance 30-60 ml/min), it is recommended to start treatment with the
adequate dosage of the free combination.
In patients with creatinine clearance greater than or equal to
Baca dokumen lengkapnya
